Abstract
Indacaterol is a novel, inhaled, long-acting β(2)-agonist providing 24-h bronchodilation with once-daily (o.d.) dosing in patients with COPD. In this double-blind, incomplete block crossover study, patients with moderate-to-severe COPD were randomised to receive three treatment cycles from: indacaterol 300μg o.d. dosed PM or AM, salmeterol 50μg twice daily or placebo, each for 14 days. Trough FEV(1) was measured 24h after indacaterol, and 12h after salmeterol. Ninety-six patients (mean age: 64 years; post-bronchodilator FEV(1) 57% predicted, FEV(1)/FVC 55%) were randomised; 83 completed. After 14 days, the difference vs. placebo in trough FEV(1) for PM indacaterol was 200mL (p<0.001 [primary analysis]) and for AM indacaterol was 200mL (p<0.001). Compared with salmeterol, trough FEV(1) for PM indacaterol was 110mL higher (p<0.001), and for AM indacaterol was 50mL higher (p=NS). Over 14 days, vs. placebo, both PM and AM indacaterol improved the % of nights with no awakenings (by 11.9 and 8.1 points; p<0.01); the % of days with no daytime symptoms (by 6.7 and 5.5 points; p<0.05); and the % of days able to perform usual activities (by 6.7 and 7.8 points; p<0.05). Indacaterol provided 24-h bronchodilation and improvement in symptoms regardless of whether taken regularly in the morning or evening. ClinicalTrials.gov NCT00615030.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
